CASTLE ROCK, Colo., Sept. 28 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY - News) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, today announced strong results from the latest pre-FDA multi-hospital study using its AppyScore(TM) human appendicitis screen triage blood test. AspenBio has also commenced the formal regulatory approval process for the AppyScore test by applying for a pre-investigational device exemption ("IDE") from the United States Food and Drug Administration ("FDA").
